Rexahn Reports Positive Top-line Phase IIa Results For Serdaxin

Rexahn Pharmaceuticals (Rexahn) has reported top-line results from a phase IIa clinical study of Serdaxin, its major depressive disorder (MDD) drug candidate. Reportedly, the randomised, double blind, placebo controlled and dose ranging study enrolled 77 patients and was conducted at multiple sites in the US to assess the Serdaxin’s safety and preliminary efficacy.

The study showed that patients ages 18-65 with MDD exhibited clinically meaningful improvement over baseline in symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. The company claimed that a marked clinical response was observed within two weeks in patients taking Serdaxin. Additionally, a significantly lower drop-out rate among patients taking Serdaxin compared with those patients taking a placebo was observed.

Chang Ahn, chairman and CEO at Rexahn, said: “Serdaxin clinical trials continue to demonstrate unprecedented efficacy, much faster onset of action compared to currently marketed drugs, and lifestyle benefits for patients with major depressive disorder. The continued strength of Serdaxin’s clinical trial data further solidifies Serdaxin as a potentially new and preferable therapy in the standard of care for this disease.”